Loading clinical trials...
Loading clinical trials...
Data analyses and revision of the DED symptoms in diabetic subjects. A novel ophthalmic solution containing cross-linked ha (CX-HA) and Chondroitin sulphate (CS) has been made available on the market. Both molecules have been widely studied for their viscoelastic and hydrating properties. Nevertheless, the use of CS in ophthalmology has been limited since, routinely, the molecule is of animal origins. This new ophthalmic solution is the first on the market formulated with a CS of non-animal origin.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
San Giovanni-Addolorata Hospital
Rome, Italy
Start Date
September 1, 2021
Primary Completion Date
September 1, 2022
Completion Date
September 1, 2022
Last Updated
August 29, 2024
20
ACTUAL participants
CX-HA and CS
DEVICE
Lead Sponsor
D&V FARMA srl
Collaborators
NCT07463950
NCT07396441
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions